Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	The supplier of the reagents are written in Method-Assays section.	

Cell materials	Yes (indicate where provided:section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	We didn't use cell lines in our study.	√
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	We didn't use primary cultures in our study.	√

Experimental animals	Yes (indicate where provided:section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	We didn't use laboratory animals in our study.	√
Animal observed in or captured from the field: Provide species, sex and age where possible	We didn't use animals in our study.	√
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	We didn't use model organisms in our study.	√

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	We didn't use plants in our study.	√
Microbes: provide species and strain, unique accession number if available, and source	We didn't use microbes in our study.	√

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	We mentioned it in Methods-Method comparison and bias estimation	√
Provide statement confirming informed consent obtained from study participants.	We didn't need informed consent in our study.	√
Report on age and sex for all study participants.	There are no participants in our study. Methods section.	√

Design

Studyprotocol	Yes (indicate where provided:section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	Our study is not a clinical trial.	√

Laboratoryprotocol	Yes (indicate where provided:section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	CLSI EP15-A3 and CLSI EP9-A3	

Experimental study design (statistics details)	Yes (indicate where provided:section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	They were not carried out	
Randomisation	They were not carried out	
Blinding	They were not carried out	
Inclusion/exclusion criteria	They were not carried out	

Sample definition and in-laboratory replication	Yes (indicate where provided:section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	The measurements were done twice.	
Define whether data describe technical or biological replicates	None	√

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Since the serum samples were collected after routine measurements were finished, the conducted research did not need ethical approval.	√
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	We didn't use animals in our study.	√
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Since the serum samples were collected after routine measurements were finished, the conducted research did not need ethical approval.	√

Dual Use Research of Concern (DURC)	Yes (indicate where provided:section/paragraph)	n/a
If study is subject to dual use research ofconcern, statethe authority granting approval and reference number for the regulatory approval	Our study is not a dual use research of concern.	√

Analysis

Attrition	Yes (indicate where provided:section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	No data point from the analysis is excluded	

Statistics	Yes (indicate where provided:section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	The statistical tests are described in Methods-Statistical Analysis.	

Data Availability	Yes (indicate where provided:section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	The protocol is available in CLSI EP15A3 and CLSI EP9A3.	
If data are publicly available, provide accession number in repository or DOI or URL.	Data is not available publicly. I can send the data through my e-mail address: giraybozkaya@yahoo.com	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Publicly available data is not used.	

Code Availability	Yes (indicate where provided:section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	Methods-Statistical Analysis	
State whether the code or software is available.	The licenced software is written in Methods-Statistical Analysis	
If code is publicly available, provide accession number in repository, or DOI or URL.	www.medcalc.org	

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	I accept.	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/atm-20-6104